Incidence of New-Onset Hypertension Post–COVID-19: Comparison With Influenza

Hypertension, Journal Year: 2023, Volume and Issue: 80(10), P. 2135 - 2148

Published: Aug. 21, 2023

SARS-CoV-2 may trigger new-onset persistent hypertension. This study investigated the incidence and risk factors associated with hypertension during COVID-19 hospitalization at ≈6-month follow-up compared influenza.This retrospective observational was conducted in a major academic health system New York City. Participants included 45 398 patients (March 2020 to August 2022) 13 864 influenza (January 2018 without history of hypertension.At 6-month follow-up, seen 20.6% hospitalized 10.85% nonhospitalized COVID-19. Persistent among did not vary across pandemic, whereas that decreased from 20% March ≈10% October (R2=0.79, P=0.003) then plateaued thereafter. Hospitalized were 2.23 ([95% CI, 1.48-3.54]; P<0.001) times 1.52 1.22-1.90]; P<0.01) more likely develop than counterparts. common older adults, males, Black, preexisting comorbidities (chronic obstructive pulmonary disease, coronary artery chronic kidney disease), those who treated pressor corticosteroid medications. Mathematical models predicted 79% 86% accuracy. In addition, 21.0% no prior developed hospitalization.Incidence is higher influenza, constituting burden given sheer number Screening at-risk for following illness be warranted.

Language: Английский

---

Long-Term Autoimmune Inflammatory Rheumatic Outcomes of COVID-19

Annals of Internal Medicine, Journal Year: 2024, Volume and Issue: 177(3), P. 291 - 302

Published: March 1, 2024

Background: Some data suggest a higher incidence of diagnosis autoimmune inflammatory rheumatic diseases (AIRDs) among patients with history COVID-19 compared uninfected patients. However, these studies had methodological shortcomings. Objective: To investigate the effect on long-term risk for incident AIRD over various follow-up periods. Design: Binational, longitudinal, propensity-matched cohort study. Setting: Nationwide claims-based databases in South Korea (K-COV-N cohort) and Japan (JMDC cohort). Participants: 10 027 506 Korean 12 218 680 Japanese aged 20 years or older, including those between 1 January 2020 31 December 2021, matched to influenza infection control Measurements: The primary outcome was onset (per appropriate codes from International Classification Diseases, 10th Revision) 1, 6, months after respective index date Results: Between participants (mean age, 48.4 [SD, 13.4]; 50.1% men), 394 274 (3.9%) 98 596 (0.98%) influenza, respectively. After propensity score matching, beyond first 30 days infection, were at increased (adjusted hazard ratio, 1.25 [95% CI, 1.18 1.31]) influenza-infected 1.30 [CI, 1.02 1.59]). more severe acute COVID-19. Similar patterns observed cohort. Limitations: Referral bias due pandemic; residual confounding. Conclusion: SARS-CoV-2 associated without infection. greater severity Primary Funding Source: National Research Foundation Korea.

Language: Английский

---

Long term outcomes of patients with chronic kidney disease after COVID-19 in an urban population in the Bronx

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 19, 2025

Abstract We investigated the long-term kidney and cardiovascular outcomes of patients with chronic disease (CKD) after COVID-19. Our retrospective cohort consisted 834 CKD COVID-19 6,167 without between 3/11/2020 to 7/1/2023. Multivariate competing risk regression models were used estimate (as adjusted hazard ratios (aHR) 95% confidence intervals (CI)) progression a more advanced stage (Stage 4 or 5) major adverse events (MAKE), (MACE) at 6-, 12-, 24-month follow up. Hospitalized 12 24 months (aHR 1.62 CI[1.24,2.13] 1.76 [1.30, 2.40], respectively), but not non-hospitalized patients, higher compared those Both hospitalized MAKE 12- 24-months 1.73 [1.21, 2.50], 1.77 [1.34, 2.33], 1.31 [1.05, 1.64], MACE increases in CKD. These findings highlight need for close up care therapies that slow this high-risk subgroup.

Language: Английский

---

New‐onset type 1 diabetes in children and adolescents as postacute sequelae of SARS‐CoV‐2 infection: A systematic review and meta‐analysis of cohort studies

Journal of Medical Virology, Journal Year: 2023, Volume and Issue: 95(6)

Published: June 1, 2023

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in children and adolescents may increase risk for a variety of post‐acute sequelae including new‐onset type 1 diabetes mellitus (T1DM). Therefore, this meta‐analysis aims to estimate the developing as SARS‐CoV‐2 infection. PubMed/MEDLINE, CENTRAL, EMBASE were systematically searched up March 20, 2023. A systematic review subsequent meta‐analyses performed calculate pooled effect size, expressed ratio (RR) with corresponding 95% confidence interval (CI) each outcome based on one‐stage approach random‐effects sizes generated use DerSimonian‐Laird method. Eight reports from seven studies involving 11 220 530 participants (2 140 897 patients history diagnosed 9 079 633 respective control groups) included. The included reported data four U.S. medical claims databases covering more than 503 million (IQVIA, HealthVerity, TriNetX, Cerner Real‐World Data), three national health registries all Norway, Scotland, Denmark. It was shown that T1DM following 42% (95% CI 13%−77%, p = 0.002) higher compared non‐COVID‐19 groups. significantly (67%, 32 %–112%, 0.0001) between 0 years, but not those 12 17 years (RR 1.10, 0.54–2.23, 0.79). We also found only exists United States 1.70, 1.37−2.11, 0.00001) Europe 1.02, 0.67−1.55, 0.93). Furthermore, we associated an elevation diabetic ketoacidosis (DKA) groups 2.56, 1.07−6.11, 0.03). Our findings mainly obtained US databases, suggest is adolescents. These highlight need targeted measures raise public practitioners physician awareness provide intervention strategies reduce who have had COVID‐19.

Language: Английский

---

Short- and Long-Term Chest-CT Findings after Recovery from COVID-19: A Systematic Review and Meta-Analysis

Diagnostics, Journal Year: 2024, Volume and Issue: 14(6), P. 621 - 621

Published: March 14, 2024

While ground-glass opacity, consolidation, and fibrosis in the lungs are some of hallmarks acute SAR-CoV-2 infection, it remains unclear whether these pulmonary radiological findings would resolve after symptoms have subsided. We conducted a systematic review meta-analysis to evaluate chest computed tomography (CT) abnormalities stratified by COVID-19 disease severity multiple timepoints post-infection. PubMed/MEDLINE was searched for relevant articles until 23 May 2023. Studies with COVID-19-recovered patients follow-up CT at least 12 months post-infection were included. evaluated short-term (1–6 months) long-term (12–24 follow-ups (severe non-severe). A generalized linear mixed-effects model random effects used estimate event rates findings. total 2517 studies identified, which 43 met inclusion (N = 8858 patients). Fibrotic-like changes had highest rate (0.44 [0.3–0.59]) (0.38 [0.23–0.56]) follow-ups. meta-regression showed that over time decreased any abnormality (β −0.137, p 0.002), opacities −0.169, < 0.001), increased honeycombing 0.075, 0.03), did not change fibrotic-like changes, bronchiectasis, reticulation, interlobular septal thickening (p > 0.05 all). The severe subgroup significantly higher bronchiectasis 0.02), reticulation 0.001) when compared non-severe subgroup. In conclusion, significant remained up 2 years post-COVID-19, especially disease. Long-lasting post-SARS-CoV-2 infection signal future public health concern, necessitating extended monitoring, rehabilitation, survivor support, vaccination, ongoing research targeted therapies.

Language: Английский

---

Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment

PLoS Medicine, Journal Year: 2024, Volume and Issue: 21(4), P. e1004263 - e1004263

Published: April 4, 2024

Background Acute neurological manifestation is a common complication of acute Coronavirus Disease 2019 (COVID-19) disease. This retrospective cohort study investigated the 3-year outcomes patients with and without significant manifestations during initial COVID-19 hospitalization. Methods findings Patients hospitalized for Severe Respiratory Syndrome 2 (SARS-CoV-2) infection between 03/01/2020 4/16/2020 in Montefiore Health System Bronx, an epicenter early pandemic, were included. Follow-up data was captured up to 01/23/2023 (3 years post-COVID-19). consisted 414 1,199 propensity-matched (for age severity score) manifestations. Neurological involvement phase included stroke, new or recrudescent seizures, anatomic brain lesions, presence altered mentation evidence impaired cognition arousal, neuro-COVID-19 complex (headache, anosmia, ageusia, chemesthesis, vertigo, presyncope, paresthesias, cranial nerve abnormalities, ataxia, dysautonomia, skeletal muscle injury normal orientation arousal signs). There no group differences female sex composition (44.93% versus 48.21%, p = 0.249), ICU IMV status, white, not Hispanic (6.52% 7.84%, 0.380), (33.57% 38.20%, 0.093), except black non-Hispanic (42.51% 36.03%, 0.019). Primary mortality, heart attack, major adverse cardiovascular events (MACE), reinfection, hospital readmission post-discharge. Secondary neuroimaging (hemorrhage, active prior mass effect, microhemorrhages, white matter changes, microvascular disease (MVD), volume loss). More discharged rehabilitation (10.39% 3.34%, < 0.001) skilled nursing facilities (35.75% 25.35%, fewer home (50.24% 66.64%, than matched controls. Incidence any reason (65.70% 60.72%, 0.036), stroke (6.28% 2.34%, 0.001), MACE (20.53% 16.51%, 0.032) higher Per Kaplan–Meier univariate survival curve analysis, such more likely die post-discharge compared controls (hazard ratio: 2.346, (95% confidence interval (CI) [1.586, 3.470]; 0.001)). Across both cohorts, causes death (13.79% neurological, 15.38% control), sepsis (8.63%, 17.58%), influenza pneumonia (13.79%, 9.89%), (10.34%, 7.69%), respiratory distress syndrome (ARDS) 6.59%). Factors associated mortality after leaving involved (odds ratio (OR): 1.802 CI [1.237, 2.608]; 0.002)), discharge disposition (OR: 1.508 [1.276, 1.775]; 0.001)), congestive failure 2.281 [1.429, 3.593]; score 1.177 [1.062, 1.304]; older 1.027 [1.010, 1.044]; 0.002)). radiological findings, that showed significantly age-adjusted loss ( 0.045) The study’s patient limited infected first wave when hospitals overburdened, vaccines yet available, treatments limited. Patient profiles might differ interrogating subsequent waves. Conclusions had worse long-term These raise awareness need closer monitoring timely interventions manifestations, as their course involving enhanced morbidity mortality.

Language: Английский

---

SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population

Multiple Sclerosis and Related Disorders, Journal Year: 2024, Volume and Issue: 86, P. 105613 - 105613

Published: April 8, 2024

Language: Английский

---

Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people

The Lancet Diabetes & Endocrinology, Journal Year: 2024, Volume and Issue: 12(8), P. 558 - 568

Published: July 23, 2024

Some studies have shown that the incidence of type 2 diabetes increases after a diagnosis COVID-19, although evidence is not conclusive. However, effects COVID-19 vaccine on this association, or effect other subtypes, are clear. We aimed to investigate association between and 2, 1, gestational non-specific diabetes, COVID- 19 vaccination, up 52 weeks diagnosis.

Language: Английский

---

Does COVID-19 Infection Increase the Risk of Diabetes? Current Evidence

Current Diabetes Reports, Journal Year: 2023, Volume and Issue: 23(8), P. 207 - 216

Published: June 7, 2023

Abstract Purpose of Review Multiple studies report an increased incidence diabetes following SARS-CoV-2 infection. Given the potential global burden diabetes, understanding effect in epidemiology is important. Our aim was to review evidence pertaining risk incident after COVID-19 Recent Findings Incident by approximately 60% compared patients without Risk also non-COVID-19 respiratory infections, suggesting SARS-CoV-2-mediated mechanisms rather than general morbidity illness. Evidence mixed regarding association between infection and T1D. associated with elevated T2D, but it unclear whether persistent over time or differs severity time. Summary diabetes. Future should evaluate vaccination, viral variant, patient- treatment-related factors that influence risk.

Language: Английский

---

Diabetes Mellitus, Energy Metabolism, and COVID-19

Endocrine Reviews, Journal Year: 2023, Volume and Issue: 45(2), P. 281 - 308

Published: Nov. 2, 2023

Abstract Obesity, diabetes mellitus (mostly type 2), and COVID-19 show mutual interactions because they are not only risk factors for both acute chronic manifestations, but also alters energy metabolism. Such metabolic alterations can lead to dysglycemia long-lasting effects. Thus, the pandemic has potential a further rise of pandemic. This review outlines how preexisting spanning from excess visceral adipose tissue hyperglycemia overt may exacerbate severity. We summarize different effects SARS-CoV-2 infection on key organs tissues orchestrating metabolism, including tissue, liver, skeletal muscle, pancreas. Last, we provide an integrative view derangements that occur during COVID-19. Altogether, this allows better understanding occurring when fire starts small flame, thereby help reducing impact

Language: Английский

---